Publications by Jan Terje Andersen
65 publications found
Publications 2021
-
The neonatal Fc receptor in mucosal immune regulation
Scand J Immunol, 93 (2), e13017
DOI 10.1111/sji.13017, PubMed 33351196 -
Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses
Vaccine (in press)
DOI 10.1016/j.vaccine.2021.02.012, PubMed 33612340
Publications 2020
-
Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin
J Control Release, 327, 161-173
DOI 10.1016/j.jconrel.2020.08.005, PubMed 32771477 -
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics
Sci Transl Med, 12 (565)
DOI 10.1126/scitranslmed.abb0580, PubMed 33055243 -
Intracellular neutralisation of rotavirus by VP6-specific IgG
PLoS Pathog, 16 (8), e1008732
DOI 10.1371/journal.ppat.1008732, PubMed 32750093 -
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
Proc Natl Acad Sci U S A, 117 (40), 25018-25025
DOI 10.1073/pnas.2010540117, PubMed 32943538 -
FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity
J Exp Med, 217 (10)
DOI 10.1084/jem.20200359, PubMed 32658257 -
Kan ampullene med covid-19-vaksine utnyttes bedre?
Tidsskr Nor Laegeforen, 140 (2)
DOI 10.4045/tidsskr.20.1039, PubMed 33528143 -
NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies
MAbs, 12 (1), 1686319
DOI 10.1080/19420862.2019.1686319, PubMed 31671278 -
An intact C-terminal end of albumin is required for its long half-life in humans
Commun Biol, 3 (1), 181
DOI 10.1038/s42003-020-0903-7, PubMed 32313072
Publications 2019
-
Complement C4 Prevents Viral Infection through Capsid Inactivation
Cell Host Microbe, 25 (4), 617-629.e7
DOI 10.1016/j.chom.2019.02.016, PubMed 30926239 -
TRIM21-From Intracellular Immunity to Therapy
Front Immunol, 10, 2049
DOI 10.3389/fimmu.2019.02049, PubMed 31555278 -
Antibody and DNA sensing pathways converge to activate the inflammasome during primary human macrophage infection
EMBO J, 38 (21), e101365
DOI 10.15252/embj.2018101365, PubMed 31468569 -
A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes
Sci Rep, 9 (1), 18021
DOI 10.1038/s41598-019-54226-7, PubMed 31792234 -
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
Eur J Nucl Med Mol Imaging, 46 (11), 2311-2321
DOI 10.1007/s00259-019-04417-1, PubMed 31309259 -
The Neonatal Fc Receptor (FcRn): A Misnomer?
Front Immunol, 10, 1540
DOI 10.3389/fimmu.2019.01540, PubMed 31354709 -
Publisher Correction: Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies
Nat Nanotechnol, 14 (4), 398
DOI 10.1038/s41565-019-0404-3, PubMed 30783200 -
Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies
Nat Nanotechnol, 14 (2), 184-190
DOI 10.1038/s41565-018-0336-3, PubMed 30643273
Publications 2018
-
TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination
Proc Natl Acad Sci U S A, 115 (41), 10440-10445
DOI 10.1073/pnas.1806314115, PubMed 30209217 -
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Nat Commun, 9 (1), 621
DOI 10.1038/s41467-018-03061-x, PubMed 29434196 -
Human and mouse albumin bind their respective neonatal Fc receptors differently
Sci Rep, 8 (1), 14648
DOI 10.1038/s41598-018-32817-0, PubMed 30279529 -
Animal models for evaluation of albumin-based therapeutics
Curr. Opin. Chem. Eng., 19, 68-76 -
Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties
Sci Rep, 8 (1), 2101
DOI 10.1038/s41598-018-20525-8, PubMed 29391560 -
Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport
Mol Immunol, 95, 1-9
DOI 10.1016/j.molimm.2018.01.006, PubMed 29367080
Publications 2017
-
Corrigendum: Antibody-antigen kinetics constrain intracellular humoral immunity
Sci Rep, 7, 45418
DOI 10.1038/srep45418, PubMed 28382939 -
Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury
Proc Natl Acad Sci U S A, 114 (14), E2862-E2871
DOI 10.1073/pnas.1618291114, PubMed 28330995
Publications 2016
-
Antibody-antigen kinetics constrain intracellular humoral immunity
Sci Rep, 6, 37457
DOI 10.1038/srep37457, PubMed 27881870 -
Dissecting the interaction between transglutaminase 2 and fibronectin
Amino Acids, 49 (3), 489-500
DOI 10.1007/s00726-016-2296-y, PubMed 27394141 -
TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization Activity
J Immunol, 196 (8), 3452-3459
DOI 10.4049/jimmunol.1502601, PubMed 26962230
Publications 2015
-
The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery
J Control Release, 211, 144-62
DOI 10.1016/j.jconrel.2015.06.006, PubMed 26055641 -
Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies
FEBS J, 282 (11), 2063-75
DOI 10.1111/febs.13276, PubMed 25808416 -
Structural Basis for Antigen Recognition by Transglutaminase 2-specific Autoantibodies in Celiac Disease
J Biol Chem, 290 (35), 21365-75
DOI 10.1074/jbc.M115.669895, PubMed 26160175 -
Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications
Sci Rep, 5, 9526
DOI 10.1038/srep09526, PubMed 25912958 -
Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization
J Control Release, 223, 42-52
DOI 10.1016/j.jconrel.2015.12.033, PubMed 26718855 -
TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity
Immunol Rev, 268 (1), 328-39
DOI 10.1111/imr.12363, PubMed 26497531 -
Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions
J Immunol, 194 (11), 5497-508
DOI 10.4049/jimmunol.1401218, PubMed 25904551 -
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
Front Immunol, 5, 682
DOI 10.3389/fimmu.2014.00682, PubMed 25674083
Publications 2014
-
Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding
J Biol Chem, 289 (19), 13492-502
DOI 10.1074/jbc.M114.549832, PubMed 24652290 -
On the perplexingly low rate of transport of IgG2 across the human placenta
PLoS One, 9 (9), e108319
DOI 10.1371/journal.pone.0108319, PubMed 25251461 -
Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn
Immunobiology, 220 (4), 452-9
DOI 10.1016/j.imbio.2014.11.003, PubMed 25468724 -
The arabidopsis histone methyltransferase SUVR4 binds ubiquitin via a domain with a four-helix bundle structure
Biochemistry, 53 (13), 2091-100
DOI 10.1021/bi401436h, PubMed 24625295 -
Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn)
J Biol Chem, 289 (50), 34583-94
DOI 10.1074/jbc.M114.587675, PubMed 25344603 -
Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies
J Biol Chem, 289 (24), 17228-39
DOI 10.1074/jbc.M113.522565, PubMed 24764301
Publications 2013
-
Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics
J Biol Chem, 288 (33), 24277-85
DOI 10.1074/jbc.M113.463000, PubMed 23818524 -
Selection of nanobodies that target human neonatal Fc receptor
Sci Rep, 3, 1118
DOI 10.1038/srep01118, PubMed 23346375 -
B-cell tolerance to the B-cell receptor variable regions
Eur J Immunol, 43 (10), 2577-87
DOI 10.1002/eji.201243203, PubMed 23839948 -
Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation
J Immunol, 191 (9), 4769-77
DOI 10.4049/jimmunol.1301653, PubMed 24062486 -
Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions
Blood, 122 (7), 1174-81
DOI 10.1182/blood-2012-12-473843, PubMed 23843496
Publications 2012
-
Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
Nat Commun, 3, 610
DOI 10.1038/ncomms1607, PubMed 22215085 -
Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life
J Biol Chem, 287 (27), 22927-37
DOI 10.1074/jbc.M112.355131, PubMed 22570488 -
Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity
ACS Chem Biol, 8 (2), 368-75
DOI 10.1021/cb300455f, PubMed 23030766 -
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance
Protein Eng Des Sel, 26 (3), 187-93
DOI 10.1093/protein/gzs096, PubMed 23175797
Publications 2011
-
Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells
Proc Natl Acad Sci U S A, 108 (24), 9927-32
DOI 10.1073/pnas.1019037108, PubMed 21628593 -
Polymeric human Fc-fusion proteins with modified effector functions
Sci Rep, 1, 124
DOI 10.1038/srep00124, PubMed 22355641 -
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
Nat Commun, 2, 599
DOI 10.1038/ncomms1608, PubMed 22186895
Publications 2010
-
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain
J Biol Chem, 286 (7), 5234-41
DOI 10.1074/jbc.M110.164848, PubMed 21138843
Publications 2009
-
Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding
J Biol Chem, 285 (7), 4826-36
DOI 10.1074/jbc.M109.081828, PubMed 20018855 -
FcRn binding properties of an abnormal truncated analbuminemic albumin variant
Clin Biochem, 43 (4-5), 367-72
DOI 10.1016/j.clinbiochem.2009.12.001, PubMed 20006594 -
The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics
Drug Metab Pharmacokinet, 24 (4), 318-32
DOI 10.2133/dmpk.24.318, PubMed 19745559
Publications 2008
-
Identification of a high affinity FcgammaRIIA-binding peptide that distinguishes FcgammaRIIA from FcgammaRIIB and exploits FcgammaRIIA-mediated phagocytosis and degradation
J Biol Chem, 284 (2), 1126-35
DOI 10.1074/jbc.M803584200, PubMed 18957413 -
Dependence of antibody-mediated presentation of antigen on FcRn
Proc Natl Acad Sci U S A, 105 (27), 9337-42
DOI 10.1073/pnas.0801717105, PubMed 18599440
Publications 2007
-
A strategy for bacterial production of a soluble functional human neonatal Fc receptor
J Immunol Methods, 331 (1-2), 39-49
DOI 10.1016/j.jim.2007.11.003, PubMed 18155020 -
A receptor-mediated mechanism to support clinical observation of altered albumin variants
Clin Chem, 53 (12), 2216
DOI 10.1373/clinchem.2007.097071, PubMed 18267931
Publications 2006
-
The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin
Eur J Immunol, 36 (11), 3044-51
DOI 10.1002/eji.200636556, PubMed 17048273
Publications 2005
-
Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells
J Immunol Methods, 298 (1-2), 93-104
DOI 10.1016/j.jim.2005.01.002, PubMed 15847800